Yesterday, shares of Valeant Pharmaceuticals International plunged as much as 20%, building on weeks of losses, reports Reuters.

Reuters adds that these previous losses were mainly due to “concerns about [Valeant’s] ties to specialty pharmacy Philidor Rx Services and its sharp drug price increases,” and those ties have since been cut. Read more.

Also read:

Valeant rebuffs explosive allegations

4 ways to enhance Canadian healthcare

2 ways to invest in U.S. healthcare

Originally published on

Add a comment

You must be logged in to comment.

Register on